Increases in Utilities, Outsourced Contract Testing Costs, Personnel Costs at Overseas Subsidiaries, and Other Expenses
First written in FY2023-Q3. . Latest entry: FY2026.
The whole theme swung hardest in 2020: 6 of 21 companies on the "Worse" side.
9 other companies' latest entry also says "Other".
- FY2026Full-year cost reduction following KMT’s liquidationAnnual report
「In terms of earnings, cost of sales decreased from the same period of the previous year following the liquidation of KMT Hepatech, Inc., a subsidiary that operated overseas production facilities. Selling, general and administrative expenses also declined as the unit cost of manufacturing PXB mice used for labor costs and research and development decreased, and the resulting cost reductions led to a return to operating profitability.」
The liquidation of KMT Hepatech, Inc. and the decline in the manufacturing unit cost of PXB mice reduced cost of sales and selling, general and administrative expenses, with the resulting cost reductions leading to a return to operating profitability. - FY2026-H1Cost reduction following the end of KMT production and other factorsAnnual report
「In terms of earnings, cost of sales decreased from the same period of the previous year because KMT Hepatech,Inc., a subsidiary that operated overseas production facilities, ended its production activities. Selling, general and administrative expenses also decreased because the unit manufacturing cost of PXB mice used for personnel and research and development expenses declined, and the resulting cost reductions contributed to securing an operating profit.」
The company stated that the end of KMT’s production activities and the decline in the unit manufacturing cost of PXB mice reduced cost of sales and selling, general and administrative expenses, and that the resulting cost reductions led to an operating profit. - FY2025Operating loss due to higher R&D and personnel expensesAnnual report
「In terms of earnings, cost of sales decreased due in part to a decline in outsourced contract testing projects, but research and development expenses increased. As a result, the decline in net sales led to an operating loss.」
Although cost of sales decreased as outsourced contract testing projects declined, research and development expenses increased, and the decline in net sales resulted in an operating loss. - FY2025-H1Operating loss due to higher R&D and personnel expensesAnnual report
「In terms of earnings, cost of sales decreased due in part to a decline in outsourced contract testing projects, but research and development expenses and personnel expenses increased. As a result, the decline in net sales led to an operating loss.」
Although cost of sales decreased as outsourced contract testing projects declined, research and development expenses and personnel expenses increased, and the decline in net sales resulted in an operating loss. - FY2024-Q3Decline in profit due to higher personnel and material costsAnnual report
「In terms of earnings, although outsourced contract testing costs decreased in cost of sales, personnel expenses and material costs increased, while operating expenses, including personnel expenses, also increased in selling, general and administrative expenses. As a result, operating profit fell substantially below that of the same period of the previous year.」
The company stated that although outsourced contract testing costs for contract testing decreased, personnel and material costs and operating expenses increased, causing operating profit to fall substantially below that of the same period of the previous year. - FY2024-Q2Update to second-quarter cost increases and impact on operating lossAnnual report
「In terms of earnings, personnel expenses, utilities and other costs increased in cost of sales, while operating expenses, including personnel expenses, also increased in selling, general and administrative expenses, resulting in an operating loss.」
The company stated that increases in personnel expenses, utilities and operating expenses included in selling, general and administrative expenses resulted in an operating loss for the cumulative second quarter. - FY2024-Q1Update to first-quarter cost increase factorsAnnual report
「In terms of earnings, outsourced contract testing costs, personnel expenses, utilities and other costs increased in cost of sales, while operating expenses, including personnel expenses, also increased in selling, general and administrative expenses. As a result, operating profit decreased substantially from the same period of the previous year.」
The company stated that increases in outsourced contract testing costs, personnel expenses, utilities and operating expenses included in selling, general and administrative expenses resulted in a substantial year-on-year decrease in operating profit. - FY2023Update to full-year cost increase factorsAnnual report
「In terms of earnings, although all costs, including raw materials, personnel expenses and transportation costs, were increasing, higher net sales enabled the company to return to profitability, resulting in operating profit of ¥508.448 million.」
The company described increases in costs including raw materials, personnel expenses and transportation costs, while stating that higher net sales enabled it to secure operating profit of ¥508.448 million. - FY2023-Q3First statedAnnual report
「In terms of expenses, although utilities, including electricity charges, and outsourced contract testing costs increased cost of sales, cost of sales fell below the same period of the previous year due to a decrease in depreciation expenses resulting from the impairment loss on overseas production facilities recorded in the previous fiscal year. Selling, general and administrative expenses exceeded those of the same period of the previous year because personnel expenses increased due to additional staff at overseas subsidiaries, while freight, travel and transportation expenses also increased.」
The company recorded, for the first time as an independent theme, increases in utilities, outsourced contract testing costs, personnel expenses associated with additional staff at overseas subsidiaries, freight, and travel and transportation expenses as cost factors. Cost of sales fell below the same period of the previous year due to a decrease in depreciation expenses and other factors, while selling, general and administrative expenses exceeded those of the same period of the previous year.